

44. Qi WX et al. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. *Br J Clin Pharmacol*. 2014 Oct;78(4):748-62.
45. Zamorano JL et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2017;19(1):9-42.
46. Choueiri TK et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. *J Clin Oncol*. 2010;28(13):2280-5.
47. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. *Br J Cancer*. 2007;96(12):1788-95.
48. Kalmanti L et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. *Leukemia*. 2015;29(5):1123-32.
49. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. *J Clin Oncol*. 2015;33(35):4210-8.
50. Hochhaus A et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*. 2016;30(5):1044-54.
51. Lipton JH et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(5):612-21.
52. Damrongwatanasuk R, Fradley MG. Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia. *Curr Treat Options Cardiovasc Med*. 2017;19(4):24.
53. Brown JR et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. *Haematologica*. 2017;102(10):1796-1805.
54. Lampson BL et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. *Blood*. 2017;129(18):2581-2584.
55. Varricchi G et al. Cardiotoxicity of immune checkpoint inhibitors. *ESMO Open*. 2017 Oct 26;2(4):e000247.
56. Marty M et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. *Ann Oncol*. 2006;17(4):614-22.
57. Reichardt P et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. *Future Oncol*. 2018; <https://doi.org/10.2217/fon-2018-0210>
58. O'Brien ME et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol*. 2004;15(3):440-9.
59. Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. *Heart*. 2016;102(6):425-30.
60. Thavendiranathan P et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. *J Am Coll Cardiol*. 2014;63(25 Pt A):2751-68.
61. Negishi K et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. *J Am Soc Echocardiogr*. 2013;26(5):493-8.
62. Avila MS et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. *J Am Coll Cardiol*. 2018;71(20):2281-90.
63. Sawaya H et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circ Cardiovasc Imaging*. 2012;5(5):596-603.
64. Cardinale D et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. *Ann Oncol*. 2002;13(5):710-5.
65. Cardinale D et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. *Circulation*. 2004;109(22):2749-54.
66. Cardinale D et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *J Clin Oncol*. 2010;28(25):3910-6.
67. Lipshultz SE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. *J Clin Oncol*. 2012;30(10):1042-9.
68. Blaes AH et al. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. *Vasc Health Risk Manag*. 2015;11:591-4.
69. Pichon MF et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. *In Vivo*. 2005;19(3):567-76.
70. Cardinale D et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015;131(22):1981-8.
71. Akpek M et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail*. 2015;17(1):81-9.
72. Pituskin E et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. *J Clin Oncol*. 2017;35(8):870-877.
73. Boekhout AH et al. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial. *JAMA Oncol*. 2016;2(8):1030-7.
74. Guglin ME. Lisinopril or Carvedilol for Prevention of Trastuzumab Induced Cardiotoxicity - Lisinopril or Carvedilol for Cardiotoxicity. American College of Cardiology Annual Scientific Session. 2018; Orlando, FL/USA.
75. Pfister R et al. Kommentar zum 2016 Positionspapier der Europäischen Gesellschaft für Kardiologie (ESC) zu kardiovaskulären Komplikationen onkologischer Therapien. *Kardiologie*. 2018;12(1):19-25.

#### Korrespondenzautorin

Dr. med. Antonia Beitzen-Heineke

Universitätsklinikum Hamburg - Eppendorf  
Klinik für Onkologie, Hämatologie und KMT mit Sektion  
Pneumologie  
Universitätsklinikum Hamburg Eppendorf,  
Martinistr. 52, 20246 Hamburg  
a.beitzen-heineke@uke.de

## Retraction Note

### Retraction Note: Immuntherapie des multiplen Myeloms

Katja Weisel, Lothar Kanz

Retraction note zu: *InFo Onkologie*. 2017;20(Suppl 1):49-53

Die Autoren haben den Artikel „Immuntherapie des multiplen Myeloms“ [Weisel K, Kanz L. *InFo Onkologie*. 2017;20(Suppl 1):49-53] zurückgezogen, weil dieser in wesentlichen Teilen auf dem englischsprachigen Review „Immunologic approaches for the treatment of multiple myeloma“ von Leo Rasche, Niels Weinhold, Gareth J. Morgan, Frits van Rhee und Faith E. Davies [Rasche L et al. *Cancer Treat Rev*. 2017;55:190-9] basiert. Diese Retraction ersetzt das frühere Erratum [Weisel K, Kanz L. *InFo Onkologie*. 2018;21(2):54]. Beide Autoren haben dieser Retraction zugestimmt.

Die Online-Version des Originalartikels war zu finden unter: <https://doi.org/10.1007/s15004-017-5793-6>

Die Online-Version des Erratums ist zu finden unter: <https://doi.org/10.1007/s15004-018-5939-1>